跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 17 条关于
“Zalontamab Brengitecan”
全部
17
临床试验
7
药物
2
机构
0
资讯
8
2年前
Bispecific Antibody-Drug Conjugates Show Promise in Solid Tumor Treatment
去年
SystImmune to Present Updated Izalontamab Brengitecan Data for HER2-Negative Breast Cancer at ESMO Breast 2025
去年
Sichuan Biokin's First-in-Class EGFR/HER3 ADC Advances to Phase 3 Trials Across Multiple Cancer Types
去年
FDA Grants Breakthrough Therapy Designation to Bristol Myers Squibb and SystImmune's Iza-bren for Advanced EGFR-Mutant Lung Cancer
去年
SystImmune to Present Promising Data on Iza-bren for HER2-Negative Breast Cancer at ESMO Breast 2025
11个月前
Bristol Myers Squibb and Lilly Showcase Major Oncology Data at ESMO 2025
9个月前
FDA Approves Five Novel Lung Cancer Therapies in 2025, Advancing Precision Medicine and Immunotherapy
3个月前
EGFR Inhibitors Market Poised for 7.9% CAGR Growth Through 2036, Driven by Next-Generation TKIs, ADCs, and Bispecific Antibodies